Transpharmation buys OrganoTherapeutics to add human brain organoids
What's the deal? UK-based contract research firm TranspharmationDealroom has a profile for this one. Try Dealroom → has acquired OrganoTherapeuticsDealroom has a profile for this one. Try Dealroom →, a Luxembourg startup that builds patient-derived brain organoid models of neurodegenerative diseases. The deal, announced October 28, 2026, carries an undisclosed value. OrganoTherapeutics will continue to operate as a subsidiary.
What each side brings: Transpharmation has spent 25 years in translational in-vivo pharmacology for neuroscience, pain, and metabolic disease. OrganoTherapeutics builds human iPSC-derived brain organoid and assembloid models for Parkinson's, Huntington's, and ALS.
What's the endgame? Transpharmation wants to offer drug developers both animal and non-animal models under one roof. The aim is a more predictive path from discovery to clinical trials, giving sponsors earlier confidence in their targets and molecules.
Why now? "Following decades of slow progress, discovery in the neurodegenerative space has entered a new era," the company said, citing breakthroughs in genetics, biomarkers, and patient-derived models. Brain organoids let scientists study diseases like Parkinson's in real human cells before clinical trials.
In their words: "With the acquisition of OrganoTherapeutics we are taking our first step in the fulfilment of our ambition to build translational CRO services that include human tissues and systems," said chief executive officer Mark Duxon. Co-founder Jens Schwamborn called the move "a logical next step."
The signal: The deal fits a broader push to combine advanced human-cell models with established preclinical services. InSphero acquired PhenoVista in May to add imaging and phenotypic-assay capabilities, while Merck has expanded its organoid business after buying HUB Organoids. With no disclosed terms or commercial figures, the significance here lies in the capabilities combined, not a proven shift in market scale.
Read more: prnewswire.com
Image credit: OrganoTherapeutics
